{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Abdullah L"],"funding":["Congressionally Directed Medical Research Programs"],"pagination":["4933"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12873323"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16(1)"],"pubmed_abstract":["Gulf War Illness (GWI) affects 32% of Veterans from the 1990-1991 Gulf War. It is characterized by fatigue, mood disturbances, pain and cognitive decrements, with no FDA-approved treatment. This exploratory randomized, double-blind, placebo-controlled trial evaluated the safety and efficacy of oleoylethanolamide (OEA) supplementation in 52 Veterans with GWI (mean age 59 ± 5 SD, 94% males and 79% White). Participants received 200 mg of OEA twice daily or a matching placebo for 10 weeks, followed by a 5-week open-label OEA extension. Outcomes included the Multidimensional Fatigue Inventory (MFI-20), abbreviated Profile of Mood States (POMS), Short-Form McGill Pain Questionnaire, Veterans RAND 36-Item Health Survey (SF-36 V), Repeatable Battery for the Assessment of Neuropsychological Status "],"journal":["Scientific reports"],"pubmed_title":["Oleoylethanolamide supplementation improves mood and reduces fatigue in veterans with GWI in a 15-week randomized, double-blind, placebo-controlled exploratory clinical trial."],"pmcid":["PMC12873323"],"funding_grant_id":["GW1800045"],"pubmed_authors":["Keegan AP","Luis C","Helgager D","Sullivan K","Cseresznye A","Crawford F","Abdullah L","Rindfleisch C","Mack W","Hoffmann M","Baraniuk J","Mullan M","Huguenard CJC","Aldrich GJ","Evans JE","Paris D"],"additional_accession":[]},"is_claimable":false,"name":"Oleoylethanolamide supplementation improves mood and reduces fatigue in veterans with GWI in a 15-week randomized, double-blind, placebo-controlled exploratory clinical trial.","description":"Gulf War Illness (GWI) affects 32% of Veterans from the 1990-1991 Gulf War. It is characterized by fatigue, mood disturbances, pain and cognitive decrements, with no FDA-approved treatment. This exploratory randomized, double-blind, placebo-controlled trial evaluated the safety and efficacy of oleoylethanolamide (OEA) supplementation in 52 Veterans with GWI (mean age 59 ± 5 SD, 94% males and 79% White). Participants received 200 mg of OEA twice daily or a matching placebo for 10 weeks, followed by a 5-week open-label OEA extension. Outcomes included the Multidimensional Fatigue Inventory (MFI-20), abbreviated Profile of Mood States (POMS), Short-Form McGill Pain Questionnaire, Veterans RAND 36-Item Health Survey (SF-36 V), Repeatable Battery for the Assessment of Neuropsychological Status ","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-07-15T06:32:17.139Z","creation":"2026-06-30T03:21:41.997Z"},"accession":"S-EPMC12873323","cross_references":{"pubmed":["41513981"],"doi":["10.1038/s41598-026-35168-3"]}}